VRTX vs CRBU Stock Comparison: AI Score, Valuation, Performance and Upside
Vertex Pharmaceuticals is generally evaluated as an established, profitable biotech with a validated commercial gene-editing therapy alongside its core franchise, while Caribou Biosciences is assessed as a clinical-stage CRISPR cell therapy company entirely dependent on future trial success. The comparison contrasts a proven, cash-generative biotech against a small, pre-revenue genome-editing pure play.
Use this comparison to weigh Vertex's proven commercial execution and financial strength against Caribou Biosciences' early-stage, higher-risk CRISPR cell therapy pipeline.
VRTX holds the edge across 4 of 5 key metrics in this comparison. VRTX leads on both 1-year return (+39.26%) and forward P/E quality (24.63x vs -1.22x for CRBU), a relatively favorable combination of momentum and valuation. VRTX leads on both revenue growth (12.50%) and operating margin (38.05%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for CRBU (+669.94%) than for VRTX (+3.96%).
- Want exposure to a profitable, diversified biotech franchise
- Value a company with an already-approved commercial gene-editing therapy
- Prefer lower binary clinical trial risk than early-stage biotechs
- Are comfortable with a premium valuation reflecting franchise quality
- Are comfortable with early-stage clinical and cash-runway risk
- Believe allogeneic, off-the-shelf cell therapies represent the next wave of oncology treatment
- Want small-cap, high-risk exposure to CRISPR genome-editing technology
- Can tolerate potential dilution as the company funds clinical development
| Metric | VRTX | CRBU |
|---|---|---|
| AI score | 49.5 | 23.8 |
| AI rank | #484 | #3429 |
| Latest close | $544.52 | $1.54 |
| 1M return | +14.13% | +5.48% |
| 6M return | +12.03% | -18.95% |
| 1Y return | +39.26% | -17.65% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | VRTX | CRBU |
|---|---|---|
| 1Y ago | $13.58K (+35.8%) started 2025-09-02 | $8.19K (-18.1%) started 2025-09-02 |
| 5Y ago | $27.62K (+176.2%) started 2021-09-01 | $566.18 (-94.3%) started 2021-08-31 |
| 10Y ago | $57.47K (+474.7%) started 2016-09-01 | $943.63 (-90.6%) started 2021-07-23 |
Hypothetical — past performance does not guarantee future results.
| Metric | VRTX | CRBU |
|---|---|---|
| Market cap | $137.3B | $165.1M |
| Trailing P/E | 31.55 | N/A |
| Forward P/E | 24.63 | -1.22 |
| Price/Sales | 10.42 | 16.45 |
| EV/Revenue | 10.44 | 8.77 |
| Analyst target | $563.12 | $11.86 |
| Target upside | +3.96% | +669.94% |
| Metric | VRTX | CRBU |
|---|---|---|
| Revenue growth | 12.50% | -43.80% |
| Earnings growth | 8.00% | N/A |
| EPS growth | +8.00% | N/A |
| FCF margin | +20.88% | -593.98% |
| Operating margin | 38.05% | -1690.39% |
| Profit margin | 35.00% | 0.00% |
| ROIC proxy | 23.54% | -78.27% |
| Return on equity | 23.54% | -78.27% |
| Dividend yield | N/A | 0.00% |
| Beta | 0.30 | 2.28 |
| Debt/equity | 9.77 | 27.17 |
| Current ratio | 3.19 | 6.49 |
| Quick ratio | 2.54 | 6.36 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | VRTX | CRBU |
|---|---|---|---|
| 1Y | Growth | +35.79% | -18.09% |
| CAGR | +36.04% | -18.19% | |
| Sharpe ratio | 1.06 | 0.03 | |
| Max drawdown | 15.21% | 51.06% | |
| Max daily drop | 4.56% | 13.79% | |
| Max wkly drop | 9.32% | 24.28% | |
| 5Y | Growth | +176.21% | -94.34% |
| CAGR | +22.54% | -43.69% | |
| Sharpe ratio | 0.70 | -0.32 | |
| Max drawdown | 29.07% | 97.58% | |
| Max daily drop | 20.60% | 30.47% | |
| Max wkly drop | 20.71% | 42.49% | |
| 10Y | Growth | +474.69% | -90.56% |
| CAGR | +19.11% | -37.02% | |
| Sharpe ratio | 0.56 | -0.17 | |
| Max drawdown | 41.60% | 97.58% | |
| Max daily drop | 20.70% | 30.47% | |
| Max wkly drop | 22.29% | 42.49% |
| Category | VRTX | CRBU |
|---|---|---|
| Company | Vertex Pharmaceuticals Incorporated | Caribou Biosciences, Inc. |
| Sector | Healthcare | Biotechnology |
| Industry | Biotechnology | N/A |
| Core business | Vertex Pharmaceuticals develops and markets therapies for cystic fibrosis and is expanding into pain management, diabetes, and gene-editing treatments including an approved CRISPR-based therapy. | Caribou Biosciences is a clinical-stage biopharmaceutical company developing CRISPR genome-edited allogeneic cell therapies for cancer and autoimmune diseases. |
| Investor focus | Investors watch cystic fibrosis franchise durability, commercial uptake of its approved gene-editing therapy, and pipeline diversification progress. | Investors track clinical trial progress for its allogeneic CAR-T and CAR-NK cell therapy candidates and the company's cash runway relative to development spending. |
- Dominant, highly profitable franchise in cystic fibrosis treatments
- Approved commercial gene-editing therapy demonstrating platform validation
- Strong balance sheet funding continued pipeline diversification
- Differentiated allogeneic, off-the-shelf cell therapy approach using CRISPR editing
- Pipeline targeting both oncology and autoimmune disease applications
- Proprietary genome-editing technology platform with broad application potential
- Long-term reliance on cystic fibrosis franchise for the bulk of revenue
- New therapy launches carry commercial execution and reimbursement risk
- Complex manufacturing and delivery logistics for cell and gene therapies
- Clinical-stage company with no approved commercial products generating revenue
- Ongoing cash burn requiring careful capital management or future dilution
- Competitive and crowded cell therapy and gene-editing landscape
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.